Print

Lay Description

This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.

Category

  • Cancers and Other Neoplasms
  • Child Health
  • Multiple Sites
  • Non-Hodgkin's Lymphoma
IRB Number
20180790HU
NCT Number
NCT03698994
Open to Enrollment
Yes

Eligibility

Eligible Ages
Between 12 Months and 21 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu

Regulatory Point of Contact
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu

Principal Investigator
Anne-Marie Langevin